Abcuro develops immunotherapies to treat autoimmunity and cancer.
Abcuro has raised $200.0M in total funding. The most recent round was Series C. The last funding was announced in February 2025.
Abcuro's investors include RA Capital Management, BlackRock, Samsara BioCapital, New Enterprise Associates, Redmile Group.
Abcuro is headquartered in Newton, United States.
Abcuro develops immunotherapies to treat autoimmunity and cancer.
Abcuro is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Abcuro — Funding & Investors." VCBacked, February 12, 2025, https://www.vcbacked.co/company/abcuro. Accessed July 19, 2026.
VCBacked. (2025). Abcuro — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/abcuro
{{cite web |title=Abcuro — Funding & Investors |url=https://www.vcbacked.co/company/abcuro |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated